Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptor
US7838639B2 · kind B2 · utility
22Cited by
2References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 30, 2008 |
| Grant date | Nov 23, 2010 |
| Priority date | — |
| Expiry date | May 30, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70575
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of the present invention encompass novel receptors of the TNF family. In particular, embodiments of the invention encompass TNF Receptor in the BRAIN (TRAIN) and isolated antibodies that bind to the same. In some embodiments, isolated antibodies that bind to TRAIN are useful in regulating cell differentiation, death, and survival. Other embodiments of the invention encompass pharmaceutical compositions comprising antibodies that bind to human TRAIN.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.